✦ LIBER ✦

Survival of infants with malignant astrocytomas. A report from the childrens cancer group

✍ Scribed by J. Russell Geyer; Jonathan L. Finlay; James M. Boyett; Jeffrey Wisoff; Allan Yates; Lian Mao; Roger J. Packer

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 559 KB
Volume: 75
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19950215)75:4<1045::aid-cncr2820750422>3.0.co;2-k

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survival of infants with malignant astro

Survival of infants with malignant astrocytomas: A report from the childrens cancer group

✍ Eric D. Kramer; Milton Donaldson; Associate Professor J. Russell Geyer 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 1 views

Tumors of the pineal and suprasellar reg

Tumors of the pineal and suprasellar region: Childrens cancer study group treatment results 1960–1975. A report from childrens cancer study group

✍ William M. Wara; Derek T. Jenkin; Audrey Evans; Inta Ertel; Robert Hittle; Jorge 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 3 views

Histiocytosis X: Clinical trial of chlor

Histiocytosis X: Clinical trial of chlorambucil: A report from childrens cancer study group

✍ Lahey, M. E. ;Heyn, R. M. ;Newton, W. A. ;Shore, N. ;Smith, W. B. ;Leikin, S. ;H 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 366 KB

## Abstract A prospective study for histiocytosis X was designed to determine whether “good risk” patients, ie, those without evidence of dysfunction of liver, lung, or hemopoietic system, would respond to single agent therapy; in this case chlorambucil (CMB) used in a dose of 5 mgm/m^2^ /day. If t

Neurodevelopmental outcome of infants wi

Neurodevelopmental outcome of infants with acute lymphoblastic leukemia : A Children's Cancer Group Report

✍ Thomas A. Kaleita; Gregory H. Reaman; William E. MacLean; Harland N. Sather; J. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

The authors are thankful to a parent whose financial support provided much assistance in achieving the very high rate of follow-up neurodevelopmental evaluations. They also acknowledge the following individuals for their special efforts in locating children and helping to arrange a significant numbe

Phase I/II study of bisantrene in childh

Phase I/II study of bisantrene in childhood cancer: A report from the childrens cancer study group

✍ Movassaghi, Nasser ;Krivit, William A. ;Krailo, Mark D. ;Hammond, G. Denman 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

A phase I/II study of bisantrene using a 3-week schedule was undertaken in 171 children with refractory leukemias and solid tumors. The doses ranged from 190 to 430 mg/m2. The maximum tolerated dose for children with solid tumors and acute leukemias was 280 mg/m2 and 360 mg/m2 every 3 weeks, respect

Improvement in outcome for children with

Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the childrens cancer study group

✍ Jonathan D. Buckley; Ronald L. Chard; Robert L. Baehner; Mark E. Nesbit; Beatric 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 888 KB

The Childrens Cancer Study Group conducted four therapeutic studies on a total of 1006 children with acute nonlymphocytic leukemia from 1972 to 1983. This report describes the therapeutic strategies of these studies and examines trends in induction rates and long-term outcome over this period. The r